Alzheimer's disease (AD) is the 3rd most costly disease and the leading cause of dementia. It can linger for many years, but ultimately is fatal, the 6th leading cause of death. Alzheimer's disease (AD) is fatal and affected individuals can sometimes linger many years. Current treatments are palliative and transient, not disease modifying. This article reviews progress in the search to identify the primary AD-causing toxins. We summarize the shift from an initial focus on amyloid plaques to the contemporary concept that AD memory failure is caused by small soluble oligomers of the Ab peptide, toxins that target and disrupt particular synapses. Evidence is presented that links Ab oligomers to pathogenesis in animal models and humans, with reference to seminal discoveries from cell biology and new ideas concerning pathogenic mechanisms, including relationships to diabetes and Fragile X. These findings have established the oligomer hypothesis as a new molecular basis for the cause, diagnosis, and treatment of AD.
Introduction
At an annual cost estimated to exceed $180 billion in the US alone, Alzheimer's is the 3rd most costly disease, afflicting 1 person in 8 over 65, and almost 1 in 2 over 85 (Alzheimer's Association, 2010; Hebert, Scherr, Bienias, Bennett, & Evans, 2000) . It is the leading cause of dementia in the elderly. Progressively incapacitating, Alzheimer's disease (AD) can linger many years. The average is 8, but it can be as long as 20 (Alzheimer's Association, 2011). Ultimately, AD is fatal and is estimated to be the 6th leading cause of death.
Current treatments are palliative and transient, not disease modifying. This is not surprising, as the disease is complex with multiple clinical manifestations. Although AD is classically defined as dementia with plaques and tangles, its inherent complexity and variability have led some to suggest that AD might be a spectrum of diseases, not just one. Its complexity increases even further with the occurrence of age-related co-morbidities. The broad clinical phenotype and underlying neuropathology of AD are summarized in Table 1 .
This article reviews progress in the search for primary AD-causing toxins. Despite the complexity of AD, the symptom that first brings patients to a physician is a troubling inability to form new memories, and early AD is largely regarded as a disease of memory formation. If we could regard AD as having a single disease-initiating cytotoxin (albeit one likely elicited by multiple factors), its action minimally must provide a basis for memory dysfunction. If the toxin were to serve as an optimal target for therapeutics, its actions should also account for the major facets of AD neuropathology. We summarize here why attention has shifted away from amyloid plaques as the toxic agents of AD to the contemporary concept that memory failure is caused by small soluble oligomers of the Ab peptide, toxins that target and disrupt particular synapses. Evidence is presented that links Ab oligomers to pathogenesis in animal models and humans, with reference to seminal discoveries from cell biology and new ideas concerning pathogenic mechanisms. This evidence has established the oligomer hypothesis as an appealing molecular basis for the cause, diagnosis, and treatment of AD.
The original amyloid cascade hypothesis
Neurodegeneration in AD can be linked to multiple cellular abnormalities. At one time or another, a number of these have been considered upstream events that initiate neurological damage (e.g., anomalies in tau and the cytoskeleton; mitochondrial dysfunction and oxidative damage; inflammation and gliosis (Butterfield, Howard, & LaFontaine, 2001; Finch et al., 2001; Mandelkow & Mandelkow, 1998) ). However, at least until recently, the dominant theory for AD has attributed disease onset to the toxicity of amyloid plaques. The amyloid plaque hypothesis, or ''amyloid cascade,'' emerged in the late 1980s (Allsop et al., 1988; Selkoe, 1989) and was formalized in 1992 in a review by Hardy and Higgins (Hardy & Higgins, 1992) . The hypothesis attributed dementia to nerve cell
